目的 观察米非司酮治疗子宫肌瘤的临床疗效及安全性。方法 对2011年9月—2012年12月天津市中心妇产科医院收治的48例子宫肌瘤患者，从月经开始的3～5 d，睡前口服米非司酮10 mg/d，3个月为一个疗程，坚持服用一个疗程。检测患者治疗前、后子宫及肌瘤的体积，抽血测定血清中雌激素和孕酮的水平。结果 治疗后患者的子宫及肌瘤体积、血清激素及孕酮水平与治疗前相比差异均有显著性（P＜0.05）。结论 采用米非司酮治疗子宫肌瘤可有效减少血清雌、孕激素水平，能缩小子宫及肌瘤的大小，对子宫肌瘤症状有较好的疗效。

Objective To evaluate the clinical efficacy and safety of mifepristone in the treatment of uterine fibroids. Methods The patients (48 cases) with uterine fibroids in September, 2011 to December, 2012 in Tianjin Central Obstetrics and Gynecology Hospital were retrospectively analyzed. The patients were po administered with mifepristone (10 mg/d) before bedtime from menstruation began to 3—5 d. Three months was as one course, and they were treated for one course. Uterine and fibroid volume, levels of estrogen and progesterone in serum were measured before and after the treatment. Results Uterine and fibroid volume, serum hormones and progesterone levels were of significant difference compared with those before the treatment (P < 0.05). Conclusion The usage of mifepristone in the treatment of uterine myoma could effectively reduce the estrogen and progesterone levels in serum, and could reduce the size of uterus and myoma, which has the good effect on uterine symptoms of uterine fibroid.